Skip to main content

Advertisement

SpringerLink
Log in

Updates in the Diagnosis and Management of AL Amyloidosis

  • Multiple Myeloma (P Kapoor, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Light chain (AL) amyloidosis is an insidious progressive disease which results in significant morbidity and inevitable mortality if not diagnosed and treated promptly. This review will highlight recent developments and summarize critical clinical points and updated practice changes for the clinician in 2020.

Recent Findings

Comparative analyses of staging systems, updated prognostic tools, and treatment response criteria now allow for improved patient stratification and treatment decisions; the role of minimal residual disease in response assessment is still being assessed. Clinical and genetic predictors for long-term survivors have been highlighted. Standard-of-care front-line bortezomib and the integration of anti-CD38 monoclonal antibodies in the relapsed disease have transformed treatment approach in recent years. Various clinical trials in the pipeline include novel anti-plasma cell therapies and therapies directed against amyloid deposits which promise to further advance the treatment landscape.

Summary

Diagnosis, response assessment, and treatment paradigms for AL amyloidosis have evolved significantly in the past 15 years, translating into superior outcomes and increased chances of long-term survival for AL amyloidosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid [Internet]. Taylor & Francis. 2018;25:215–9. https://doi.org/10.1080/13506129.2018.1549825.

    Article  CAS  Google Scholar 

  2. Sakata N, Hoshii Y, Nakamura T, Kiyama M, Arai H, Omoto M, et al. Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem. 2005.

  3. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, et al. Treatment of immunoglobulin light chain amyloidosis Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clin Proc. 2015;90(8):1054–81.

    CAS  PubMed  Google Scholar 

  4. Kourelis TV, Kyle RA, Dingli D, Buadi FK, Kumar SK, Gertz MA, et al. Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience. Mayo Clin Proc. 2017;92(6):908–17.

    CAS  PubMed  Google Scholar 

  5. • Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465–71. This is the most expansive and most recent cohort of patients with AL amyloidosis, highlighing the incidence of 1.2 per 100,000 person years, and no significant increase in incidence over the past 26 years.

    PubMed  PubMed Central  Google Scholar 

  6. Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim. England. 2018;4:38.

    PubMed  Google Scholar 

  7. Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev United States. 2015;20:155–62.

    CAS  Google Scholar 

  8. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010;107:4188–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther United States. 2015;32:920–8.

    CAS  Google Scholar 

  10. Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, et al. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol. 2014;89(11):1051–4.

    PubMed  Google Scholar 

  11. Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant. 2006;38:7–15.

    CAS  PubMed  Google Scholar 

  12. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998;82(8):1501–5.

    CAS  PubMed  Google Scholar 

  13. Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma [Internet]. Taylor & Francis. 1997;27:315–9. https://doi.org/10.3109/10428199709059685.

    Article  CAS  Google Scholar 

  14. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. United States. 2013;31:4319–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, et al. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia. 2019;33(3):790–4.

    PubMed  Google Scholar 

  17. Adami F, Briani C, Binotto G, Altinier S, Tarantini G, Semenzato G. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course. Am J Hematol. 2010;85(2):131–2.

    CAS  PubMed  Google Scholar 

  18. Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood. 2005;105(2):794–803.

    CAS  PubMed  Google Scholar 

  19. Falk RH. AL amyloidosis or multiple myeloma? An important distinction. Br J Haematol [Internet]. John Wiley & Sons, ltd (10.1111). 2014;164:748–9. https://doi.org/10.1111/bjh.12677.

    Article  Google Scholar 

  20. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.

    CAS  PubMed  Google Scholar 

  21. Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. Nature Publishing Group UK. 2018;8:44.

    PubMed  PubMed Central  Google Scholar 

  22. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–32.

    CAS  PubMed  Google Scholar 

  23. Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733–48.

    PubMed  PubMed Central  Google Scholar 

  24. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82(5):291–8.

    Google Scholar 

  25. Lovat LB, Pepys MB, Hawkins PN. Amyloid and the gut. Dig Dis. 1997;15(3):155–71.

    CAS  PubMed  Google Scholar 

  26. Mumford AD, O’donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110(2):454–60.

    CAS  PubMed  Google Scholar 

  27. Halligan CS, Lacy MQ, Rajkumar SV, Dispenzieri A, Witzig TE, Lust JA, et al. Natural history of thromboembolism in AL amyloidosis. Amyloid. 2006;13(1):31–6.

    PubMed  Google Scholar 

  28. Thompson CA, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010;85(3):171–3.

    PubMed  PubMed Central  Google Scholar 

  29. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002;77:181–7.

    PubMed  Google Scholar 

  30. Mauermann ML. Paraproteinemic neuropathies. Continuum (Minneap Minn). United States. 2014;20:1307–22.

    Google Scholar 

  31. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.

    PubMed  Google Scholar 

  32. Gertz MA, Kyle RA. Primary systemic amyloidosis--a diagnostic primer. Mayo Clin Proc England. 1989;64:1505–19.

    CAS  Google Scholar 

  33. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med Interne. Taylor & Francis. 2017;49:545–51. https://doi.org/10.1080/07853890.2017.1304649.

    Article  Google Scholar 

  34. Kim MJ. Pathologic findings of amyloidosis: recent advances. In: Baek D, editor. Rijeka: IntechOpen; 2019. p. Ch. 4. Available from: https://doi.org/10.5772/intechopen.84268.

  35. • Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, et al. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia [Internet]. 2019. https://doi.org/10.1038/s41375-019-0655-x. This article reinforces the singificance of increasing bone marrow plasma cell burden and signficantly negative impact on prognosis.

  36. Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D’Souza A. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematol Oncol Stem Cell Ther. 2018;11(2):105–11.

    CAS  PubMed  Google Scholar 

  37. • Sidiqi MH, Dasari S, ED MP, Buadi FK, Warsame R, Lacy MQ, et al. Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. Am J Hematol. 2019;94(5):E141–3. This important review highlights that among patients with ATTRwt, 29% had a concurrent plasma cell disorder, majority MGUS, followed by smouldering myeloma and then muyltiple myloma. Conccurent AL amloidosis occurred in a minority of cases, thereby reinforing that a diagnosis of amyloidosis with monoclonal protein does not equal AL amyloid.

    PubMed  Google Scholar 

  38. Vrana JA, Theis JD, Dasari S, Mereuta OM, Dispenzieri A, Zeldenrust SR, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica [Internet]. 2014;99:1239 LP–1247 Available from: http://www.haematologica.org/content/99/7/1239.abstract.

    Google Scholar 

  39. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. United States. 2009;114:4957–9.

    CAS  PubMed  Google Scholar 

  40. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med [Internet]. Massachusetts Medical Society. 2002;346:1786–91. https://doi.org/10.1056/NEJMoa013354.

    Article  CAS  Google Scholar 

  41. Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood [internet]. 2012;119:488–93. Available from. https://doi.org/10.1182/blood-2011-06-358507.

    Article  CAS  Google Scholar 

  42. De Larrea CF, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015;25(14):2239–44.

    Google Scholar 

  43. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Rev Cardiovasc Ther. 2015;13:1195–211.

    CAS  PubMed  Google Scholar 

  44. • Kumar SK, Gertz MA, Dispenzieri A. Validation of Mayo Clinic staging system for light chain amyloidosis with high-sensitivity troponin. J Clin Oncol. 2019;37(2):171–3. This letter to the editor confirms that high sensitivity troponin is validated for use in the Mayo Clinic 2012 staging system.

    CAS  PubMed  Google Scholar 

  45. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Grogan M, DIspenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103(14):1065–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Dispenzieri A, Kyle RA, Lacy MQ, Jaffe AS, Therneau TM, Zeldenrust SR, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Amyloid Amyloidosis. 2004;22(18):3751–7.

    CAS  Google Scholar 

  48. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–7.

    CAS  PubMed  Google Scholar 

  49. Muchtar E, Kumar SK, Gertz MA, Grogan M, Abou Ezzeddine OF, Jaffe AS, et al. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood. 2019;133(7):763–6.

    CAS  PubMed  Google Scholar 

  50. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254–61.

    CAS  PubMed  Google Scholar 

  51. Palladini G, Milani P, Merlini G. Predicting survival in light chain amyloidosis. Haematologica [Internet]. 2019;104:1294 LP–1296 Available from: http://www.haematologica.org/content/104/7/1294.abstract.

    Google Scholar 

  52. •• Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, et al. Comparative analysis of staging systems in AL amyloidosis. Leukemia [Internet]. 2019;33:811–4. https://doi.org/10.1038/s41375-018-0370-z. The 2 stage Mayo AL Amyloidosis 2004 model proved to be less robust than the Mayo AL amyloidosis 2012 3-stage model which was better for predicting long-term survivial and European 3 stage model, which was superior for predicting 1 year mortality.

    Article  Google Scholar 

  53. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol. 2003;119(2):274–8.

    CAS  PubMed  Google Scholar 

  54. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J [Internet]. 2015;5:e310. https://doi.org/10.1038/bcj.2015.34.

    Article  CAS  Google Scholar 

  55. Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, et al. Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p. Clin Lymphoma Myeloma Leuk. 2018;8(11):e493–9.

    Google Scholar 

  56. Kobayashi H, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, et al. Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma. Jpn J Clin Oncol [Internet]. 2019;49:195–8. Available from. https://doi.org/10.1093/jjco/hyy202.

    Article  Google Scholar 

  57. Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31(7):1562–9.

    CAS  PubMed  Google Scholar 

  58. Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, et al. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv. 2018;2(20):2607–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–25.

    CAS  PubMed  Google Scholar 

  60. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9.

    CAS  PubMed  Google Scholar 

  61. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32(10):2240–9.

    PubMed  Google Scholar 

  62. Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood. 2017;29(1):82–7.

    Google Scholar 

  63. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK. The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia. 2018;32(5):1243–6.

    PubMed  Google Scholar 

  64. Palladini G, Massa M, Basset M, Russo F, Milani P, Foli A, et al. Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response. Blood. 2016;128(22):–3261.

  65. Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, et al. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid. 2019;27(1):13–6.

    PubMed  Google Scholar 

  66. • Sidiqi MH, Aljama MA, Jevremovic D, Muchtar E, Buadi FK, Warsame R, et al. Prognostic significance of stringent complete response after stem cell transplantation in immunoglobulin light chain amyloidosis. Biol Blood Marrow Transplant. 2018;24(11):2360–4. The achievement of complete stringent response defined as undetectable bone marrow clonal plasma cells by flow cytometry is associated with longer progression free survival.

    PubMed  PubMed Central  Google Scholar 

  67. Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR, et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013;48:1302–7.

    CAS  PubMed  Google Scholar 

  68. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28(7):637–42.

    CAS  PubMed  Google Scholar 

  69. Gertz MA. How to manage primary amyloidosis. Leukemia. 2012;26(2):191–8.

    CAS  PubMed  Google Scholar 

  70. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101(4):766–9.

    CAS  PubMed  Google Scholar 

  71. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood United States. 2017;129:2111–9.

    CAS  Google Scholar 

  72. D’Souza A, Dispenzieri A, Wirk B, Zhang M-J, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol: Proc Am Soc Clin Oncol. 2015;33:3741–9.

    Google Scholar 

  73. • Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36:13. At a high volume transplant center for Amyloidosis, the transplant mortality rate has decreased significantly over time to 2.4%.

    Google Scholar 

  74. Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019;94(9):1020–6.

    CAS  PubMed  Google Scholar 

  75. • Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol. 2019;187(5):588–94. Among long-term survivors with AL amyloidosis, patient specific and clone specific characteristics predict outcome: in particular, limited organ involvement at diagnosis, lower plasma cell burden, low dFLC, less frequent finding of trisomies on FISH, and achieivement of complete hematologic response.

    PubMed  Google Scholar 

  76. •• http://msmart.org/amyloidosis.pdf. msmart.org [Internet]. 2019. Available from: https://www.msmart.org/treatment-guidelines. These are recommendations and treatment guidelines for AL Amyloidosis as per the Mayo Clinic, a high volume center for management and treatment of AL amyloidosis.

  77. Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016;91(10):984–8.

    CAS  PubMed  Google Scholar 

  78. Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant. 2008;41:1013–9.

    CAS  PubMed  Google Scholar 

  79. Sidana S, Narkhede M, Elson P, Hastings D, Faiman B, Valent J, et al. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS One. 2017;12(3):e0172996.

    PubMed  PubMed Central  Google Scholar 

  80. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia [Internet]. 2013;27:823–8. Available from. https://doi.org/10.1038/leu.2012.274.

    Article  CAS  Google Scholar 

  81. Al Saleh AS, Sidiqi MH, Sidana S, Muchtar E, Dispenzieri A, Dingli D, et al. Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. Am J Hematol. 2019;94:1066–71.

    PubMed  Google Scholar 

  82. Ozga MP, Zhao Q, Benson DM, Elder P, Williams N, Bumma N, et al. AL Amyloidosis: the prognostic impact of maintenance therapy following ASCT. Biol Blood Marrow Transplant. 2020;26(3):S229–30.

    Google Scholar 

  83. Palladini G, Merlini G. When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. Blood Adv. 2019;3(2):212–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Jimenez-Zepeda VH, Duggan P, Neri P, Bahlis NJ. Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a single-center experience. Clin Lymphoma, Myeloma Leuk. 2016;16(6):e79–84.

    Google Scholar 

  85. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99(4):743–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865–73.

    CAS  PubMed  Google Scholar 

  87. Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood [Internet]. 2015;126:612–5. Available from. https://doi.org/10.1182/blood-2015-01-620302.

    Article  CAS  Google Scholar 

  88. Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood United States. 2019;134(25):2271–80.

    Google Scholar 

  89. Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant [Internet]. 2015;50:914–7. Available from. https://doi.org/10.1038/bmt.2015.73.

    Article  CAS  Google Scholar 

  90. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi F, Lacy MQ, et al. Bortezomib versus non-Bortezomib based treatment for transplant ineligible patients with light chain amyloidosis. Blood [internet]. 2016;128:3317. Available from. https://doi.org/10.1182/blood.V128.22.3317.3317.

    Article  Google Scholar 

  91. Cibeira MT, Oriol A, Lahuerta JJ, Mateos MV, de la Rubia J, Hernández MT, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015;170(6):804–13.

    CAS  PubMed  Google Scholar 

  92. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood [Internet]. 2010;116:1990–1. Available from. https://doi.org/10.1182/blood-2010-07-295485.

    Article  CAS  Google Scholar 

  94. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood [Internet]. 2012;119:4391–4. Available from. https://doi.org/10.1182/blood-2011-11-390930.

    Article  CAS  Google Scholar 

  95. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66.

    CAS  PubMed  Google Scholar 

  96. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

    CAS  PubMed  Google Scholar 

  97. Sidiqi MH, Gertz MA. Daratumumab for the treatment of AL amyloidosis. Leuk Lymphoma. 2019;60(2):295–301.

    CAS  PubMed  Google Scholar 

  98. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood [Internet]. 2017;130:900–2. Available from. https://doi.org/10.1182/blood-2017-01-763599.

    Article  CAS  Google Scholar 

  99. Van de Wyngaert Z, Carpentier B, Pascal L, Lionne-Huyghe P, Leduc I, Srour M, et al. Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. Br J Haematol [Internet]. John Wiley & Sons, Ltd (10.1111); 2019;n/a. Available from: https://doi.org/10.1111/bjh.16282.

  100. Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol. England. 2019;37(5):595–600.

    CAS  PubMed  Google Scholar 

  101. Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33(2):531–6.

    PubMed  Google Scholar 

  102. Sanchorawala V, Sarosiek S, Sloan JM, Brauneis D, Migre ME, Mistark M, et al. Safety, tolerability and response rates of daratumumab in patients with relapsed light chain (AL) amyloidosis: results of a phase II study. Blood. 2020. https://doi.org/10.1182/blood.2019004436.

  103. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114(16):3439–47.

    CAS  PubMed  Google Scholar 

  104. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): and randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.

    CAS  PubMed  Google Scholar 

  105. Cohen AD, Landau H, Scott EC, Liedtke M, Kaufman JL, Rosenzweig M, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood [Internet]. 2016;128:645. Available from. https://doi.org/10.1182/blood.V128.22.645.645.

    Article  Google Scholar 

  106. Cohen AD, Liedtke M, Scott EC, Kaufman JL, Landau H, Vesole DH, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Clin Lymphoma Myeloma Leuk. 2015;128(22):645.

    Google Scholar 

  107. Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Yong K, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol England. 2019;187:638–41.

    CAS  Google Scholar 

  108. Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017.

  109. Angela Dispenzieri, Eftathios Kastritis, Ashutosh D Wechalekar, Path DM, Stefan O. Schönland MD, Kihyun Kim, Vaishali Sanchorawala, Heather J Landau, Fiona Kwok, Kenshi Suzuki, Raymond L Comenzo, Debora GM. 139 primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician’s choice of therapy in patients (pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL). ASH Oral Abstr [Internet]. 2019; Available from: https://ash.confex.com/ash/2019/webprogram/Paper124409.html

  110. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105(7):2949–51.

    CAS  PubMed  Google Scholar 

  111. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003;10(4):257–61.

    CAS  PubMed  Google Scholar 

  112. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3(4):241–6.

    CAS  PubMed  Google Scholar 

  113. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood [Internet]. 2012;119:5397–404. Available from. https://doi.org/10.1182/blood-2012-02-413161.

    Article  CAS  Google Scholar 

  114. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood [Internet]. 2006;109:465–70. Available from. https://doi.org/10.1182/blood-2006-07-032987.

    Article  CAS  Google Scholar 

  115. Palladini G, Russo P, Foli A, Milani P, Lavatelli F, Obici L, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol. 2012;91(1):89–92.

    CAS  PubMed  Google Scholar 

  116. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010;85(10):757–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013;98(5):789–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  118. Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica [Internet]. 2017;102:1424 LP–1431 Available from: http://www.haematologica.org/content/102/8/1424.abstract.

    Google Scholar 

  119. Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, et al. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018;25(4):234–41.

    CAS  PubMed  Google Scholar 

  120. Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017; 129;(15):2120–3.

  121. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059–62.

    CAS  PubMed  Google Scholar 

  122. Scarfò L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013;155(1-2):36–9.

    PubMed  Google Scholar 

  123. Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood [Internet]. 2017;130(22):2401–9. Available from. https://doi.org/10.1182/blood-2017-06-788786.

    Article  CAS  Google Scholar 

  124. Le Bras F, Dupuis J, Lemonnier F, Oghina S, Bodez D, Ladaique A, et al. Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis. J Clin Oncol [Internet]. 2019;37:e19538 Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e19538.

    Google Scholar 

  125. Sidiqi MH, Al Saleh AS, Leung N, Aljama M, Jevremovic D, Gonsalves W, et al. Venetoclax for the treatment of translocation (11; 14) AL amyloidosis (in press). Blood Cancer. 2020;37:e19538.

    Google Scholar 

  126. Premkumar V, Comenzo R, Lentzsch S. Venetoclax in immunoglobulin light chain amyloidosis: is this the beginning or the end? Clin Lymphoma Myeloma Leuk. 2019;19(10):686–8.

    PubMed  PubMed Central  Google Scholar 

  127. Ward JE, Ren R, Toraldo G, SooHoo P, Guan J, O’Hara C, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011;118(25):6610–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Shaji K, Kumar M, Angela Dispenzieri M, Martha Q, Lacy M, Suzanne R, et al. Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation. Blood. 2012;120:3138.

    Google Scholar 

  129. Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7(3):e546.

    CAS  PubMed  PubMed Central  Google Scholar 

  130. Anita D’Souza M, Kathryn E, Flynn P, Binod Dhakal M, Saurabh Chhabra M, Marcelo C, et al. Adjuvant doxycycline to enhance anti-amyloid effects: results from the DUAL (doxycycline to upgrade response in AL amyloidosis) study. Blood [Internet]. 2018;132:1999 Available from: https://ashpublications.org/blood/article/132/Supplement 1/1999/261658/Adjuvant-Doxycycline-to-Enhance-Anti-Amyloid.

    Google Scholar 

  131. Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000;157(4):1239–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. Edwards CV, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, et al. One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid [Internet]. Taylor & Francis. 2019;26:115–6. https://doi.org/10.1080/13506129.2019.1584892.

    Article  Google Scholar 

  133. Renz M, Torres R, Dolan PJ, Tam SJ, Tapia JR, Li L, et al. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis†. Amyloid. 2016;23(3):168–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  134. Prothena discontinues development of NEOD001 for AL amyloidosis. 2018.

  135. Gertz MA, Cohen AD, Comenzo RL, Du Mond C, Kastritis E, Landau HJ, et al. Results of the phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients. Blood. 2019;134(Supplement_1):3166.

    Google Scholar 

  136. Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168:186–206.

    PubMed  Google Scholar 

  137. Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA. Selective binding of nifedipine to amylold fibrils. Am J Cardiol. 1985;37:711–2.

    Google Scholar 

  138. Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid. 2018;25(2):86–92.

    CAS  PubMed  Google Scholar 

  139. Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2013;24(7):793–8.

    PubMed  Google Scholar 

  140. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al. Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol. 2011;29(6):674–81.

    PubMed  Google Scholar 

  141. Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med. 2001;111(7):535–40.

    CAS  PubMed  Google Scholar 

  142. Tsukanov J, Del Fabbro E. Palliative care and symptom management in amyloidosis: a review. Curr Probl Cancer. 2016;40(5-6):220–8.

    PubMed  Google Scholar 

  143. Hegenbart U Abstract OP39: EGCG treatment in patients with cardiac AL amyloidosis: first results of a randomized and placebo-controlled clinical trial of GERAMY. Int Symp Amyloidosis 2018;

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA

    Joselle Cook, Eli Muchtar & Rahma Warsame

Authors
  1. Joselle Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eli Muchtar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rahma Warsame
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rahma Warsame.

Ethics declarations

Conflict of Interest

The authors declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Multiple Myeloma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cook, J., Muchtar, E. & Warsame, R. Updates in the Diagnosis and Management of AL Amyloidosis. Curr Hematol Malig Rep 15, 155–167 (2020). https://doi.org/10.1007/s11899-020-00574-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-020-00574-5

Keywords

Search

Navigation